Mason Capital Management LLC’s Kenneth M Garschina said he wants Grifols SA’s board replaced. The co-founder of the New ...

JPMorgan lowered the firm’s price target on Grifols (GRFS) to EUR 9.50 from EUR 14 and keeps a Neutral rating on the shares. Don't Miss our Black Friday Offers: Published first on TheFly – the ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the "Clients") holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in ...

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Barcelona-based Grifols has seen its stock value plummet since January, when short seller Gotham City Research accused the company of manipulating debt and earnings reporting by consolidating profit ...

La farmacéutica española Grifols SA está en conversaciones con bancos para refinanciar bonos que vencen el próximo año y ...